ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.

ACC 2021 A pooled patient-level analysis showed that sotagliflozin significantly reduced total CV deaths, HF hospitalizations, and urgent visits for HF across the full range of baseline EF, including in patients with HFpEF.

In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.

Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

This study investigated the relative risk of more than 50 clinical risk factors and biomarkers with incident CHD in 4 age groups in women.

Triglycerides and remnant-c, but not LDL-c and HDL-c, were associated with MACE in a primary prevention cohort of high CV risk subjects with high prevalence of diabetes and obesity.

The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

There are barriers to intensify treatment in T2DM patients leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.

Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.

Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.